
In 2020, Biomarin's revenue has increased from USD 1.7bn to USD 1.9bn, which is the highest revenue in the history of the still-growing US company.
The record year came about in spite of the company retreating in Q4 due to postponed orders and competition from generics.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app